(CBDRA60) to Prevent or Reduce Symptoms of COVID-19 and Prevention of Post-Acute Sequelae of SARS-CoV-2 Infection PASC

NAUnknownINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

July 1, 2022

Primary Completion Date

December 5, 2022

Study Completion Date

December 28, 2022

Conditions
COVID-19SAR
Interventions
DIETARY_SUPPLEMENT

CBDRA60 supplement

CBD is a non-psychotropic cannabinoid that has a broad spectrum of well-established anti-inflammatory and immunomodulatory effects. Red algae (Rhodophyta) are known for their potent anti-viral properties, non-toxicity and for being well tolerated in humans \[15, 16\]. Rhodophyta contain several sulfated polysaccharides that exhibit high antiviral activity against enveloped viruses.,

DIETARY_SUPPLEMENT

Placebo

Placebo

Trial Locations (1)

49250

Anewsha Therapeutics / Comco R&D, Hanover

Sponsors
All Listed Sponsors
collaborator

University of Michigan

OTHER

collaborator

Biologics Consulting

UNKNOWN

lead

Anewsha Therapeutics Inc.

INDUSTRY

NCT04777981 - (CBDRA60) to Prevent or Reduce Symptoms of COVID-19 and Prevention of Post-Acute Sequelae of SARS-CoV-2 Infection PASC | Biotech Hunter | Biotech Hunter